Candel Therapeutics, Inc.
13
1
6
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Role: lead
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Role: collaborator
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Role: lead
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Role: lead
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Role: lead
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
Role: lead
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
Role: lead
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Role: lead
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Role: lead
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Role: lead
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Role: lead
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Role: lead
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Role: lead
All 13 trials loaded